​

Corvus Pharmaceuticals (CRVS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CRVS Stock Forecast

Corvus Pharmaceuticals stock forecast is as follows: an average price target of $12.50 (represents a 133.64% upside from CRVS’s last price of $5.35) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

CRVS Price Target

The average price target for Corvus Pharmaceuticals (CRVS) is $12.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $13.00 to $12.00. This represents a potential 133.64% upside from CRVS's last price of $5.35.

CRVS Analyst Ratings

Buy

According to 2 Wall Street analysts, Corvus Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for CRVS stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Corvus Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 13, 2024Roger SongJefferies$13.00$3.97227.46%142.99%
Oct 22, 2024Graig SuvannavejhMizuho Securities$12.00$7.5658.73%124.30%
Aug 18, 2023Jeff JonesOppenheimer$7.00$2.19219.65%30.84%

The latest Corvus Pharmaceuticals stock forecast, released on Nov 13, 2024 by Roger Song from Jefferies, set a price target of $13.00, which represents a 227.46% increase from the stock price at the time of the forecast ($3.97), and a 142.99% increase from CRVS last price ($5.35).

Corvus Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts-22
Avg Price Target-$12.50$12.50
Last Closing Price$5.35$5.35$5.35
Upside/Downside-100.00%133.64%133.64%

In the current month, the average price target of Corvus Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Corvus Pharmaceuticals's last price of $5.35. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 13, 2024JefferiesBuyBuyHold
May 07, 2024OppenheimerOutperformOutperformHold
Aug 18, 2023OppenheimerOutperformInitialise

Corvus Pharmaceuticals's last stock rating was published by Jefferies on Nov 13, 2024. The company gave CRVS a "Buy" rating, the same as its previous rate.

Corvus Pharmaceuticals Financial Forecast

Corvus Pharmaceuticals Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

Corvus Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CRVS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Corvus Pharmaceuticals EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict CRVS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Corvus Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Corvus Pharmaceuticals Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-9.12M$-8.67M$-8.23M$-8.23M$-7.74M$-7.34M$-6.87M
High Forecast$-9.12M$-8.67M$-8.23M$-8.23M$-6.45M$-7.34M$-6.87M
Low Forecast$-9.12M$-8.67M$-8.23M$-8.23M$-8.38M$-7.34M$-6.87M
Surprise %-------

Corvus Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CRVS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Corvus Pharmaceuticals SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Corvus Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CRVS last annual SG&A of $NaN (undefined).

Corvus Pharmaceuticals EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-0.14$-0.13$-0.12$-0.12$-0.12$-0.11$-0.12
High Forecast$-0.14$-0.13$-0.12$-0.12$-0.10$-0.11$-0.12
Low Forecast$-0.14$-0.13$-0.12$-0.12$-0.13$-0.11$-0.12
Surprise %-------

According to undefined Wall Street analysts, Corvus Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CRVS previous annual EPS of $NaN (undefined).

Corvus Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
INZYInozyme Pharma$2.77$16.00477.62%Buy
PDSBPDS Bio$1.63$9.00452.15%Buy
XFORX4 Pharmaceuticals$0.73$3.67402.74%Buy
ABOSAcumen Pharmaceuticals$1.72$7.00306.98%Buy
TERNTerns Pharmaceuticals$5.54$18.67237.00%Buy
CRVSCorvus Pharmaceuticals$5.35$12.50133.64%Buy
MREOMereo BioPharma Group$3.50$6.7592.86%Buy
DAWNDay One Biopharmaceuticals$12.67$24.0089.42%Buy
HOOKHOOKIPA Pharma$2.01$3.0049.25%Buy

CRVS Forecast FAQ

Is Corvus Pharmaceuticals a good buy?

Yes, according to 2 Wall Street analysts, Corvus Pharmaceuticals (CRVS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of CRVS's total ratings.

What is CRVS's price target?

Corvus Pharmaceuticals (CRVS) average price target is $12.5 with a range of $12 to $13, implying a 133.64% from its last price of $5.35. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Corvus Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for CRVS stock, the company can go up by 133.64% (from the last price of $5.35 to the average price target of $12.5), up by 142.99% based on the highest stock price target, and up by 124.30% based on the lowest stock price target.

Can Corvus Pharmaceuticals stock reach $8?

CRVS's average twelve months analyst stock price target of $12.5 supports the claim that Corvus Pharmaceuticals can reach $8 in the near future.

What are Corvus Pharmaceuticals's analysts' financial forecasts?

Corvus Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-21.941M (high $-20.652M, low $-22.586M), average SG&A $0 (high $0, low $0), and average EPS is $-0.341 (high $-0.322, low $-0.351). CRVS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-34.24M (high $-34.24M, low $-34.24M), average SG&A $0 (high $0, low $0), and average EPS is $-0.513 (high $-0.513, low $-0.513).